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Introduction
Children, especially the younger age groups, 
may require age-appropriate formulations 
allowing both safe and accurate dose 
administration.3 Lack of appropriate studies 
preclude most medications from being labelled 
for use in paediatric patients.4 In order to 
improve the health of children in Europe 
without subjecting children to unnecessary 
trials, or delaying the authorisation of 
medicinal products for use in adults, the 
European Union’s Paediatric Regulation came 
into force in 2007.5
Since licensed medicines represent 
the ‘gold standard’ for quality, safety and 
efﬁcacy, the underlying general rule is that 
a licensed preparation is always preferable 
to a compounded one. Medicines are 
given a license, now called a marketing 
authorisation, if the pharmaceutical company 
has demonstrated the quality, efﬁcacy and 
safety of the medicine as recommended in the 
Summary of Product Characteristics (SmPC) 
when given in the dose and for the disease 
and age group recommended. The Standing 
Committee on Medicines has stated that in 
paediatric practice, the informed use of some 
unlicensed medicines or licensed medicines 
for unlicensed applications is necessary. 6
There are circumstances in which there 
is no licensed product or alternative which 
fully meets the clinical needs of a particular 
patient and therefore it becomes necessary to 
extemporaneously prepare a limited quantity 
of a custom-made product for an individual 
patient.7 Between 15 and 80% of all medicines 
used in hospitalised children have either not 
been licensed at all (‘unlicensed’) or are used 
outside the speciﬁcation terms of the product 
license (‘off-license’).8
Extemporaneous compounding of 
medicines carries signiﬁcant risk, as the risks 
of using unlicensed medicines are combined 
with inherent risks associated with the 
pharmaceutical compounding process.7 The 
risk for the patient is that total accuracy and 
uniformity of the dose can never be assured 
and the risk for the operator is that he/she 
is being exposed to the chemicals whilst 
reconstituting a preparation. Extemporaneous 
compounding is deﬁned as the preparation, 
mixing, assembling, packaging and labelling 
of a medicinal product based on a prescription 
order from a licensed practitioner for the 
individual patient.1 At Mater Dei Hospital, 
the extemporaneous compounding service 
caters for both children and adults, to 
both in- and out-patients and liaises with 
clinicians, pharmacists and nursing stuff to 
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Extemporaneous compounding is deﬁned as the preparation, 
mixing, assembling, packaging and labelling of a medicinal 
product based on a prescription order from a licensed 
practitioner for the individual patient.1 The lack of commercially 
available formulations for patients with speciﬁc needs poses a 
challenge to making medicines available to what are considered 
to be the most vulnerable patients.2 This qualiﬁes as off-license 
use of a medicine, whereby a licensed medicine is reformulated 
into a preparation that is acceptable/appropriate for the patient. 
s  To gain further knowledge about extemporaneous compounding of medicines 
s  To highlight the importance of extemporaneous preparations in paediatric use
s  To appreciate the need for the extemporaneous compounding of medicines locally
s  To showcase the extemporaneous preparatory service provided at Mater Dei Hospital 
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ensure seamless care. Since the majority 
of medicines are prepared for paediatric 
patients, this article will focus on this 
category of patients. 
Extemporaneous medicines can range 
from oral formulations such as suspensions 
and solutions, sachets, mouthwashes to 
topical formulations such as creams and 
ointments. Examples range from captopril 
suspension for cardiovascular disease to 
controlled medicines such as clobazam 
sachets, both for use in paediatric patients.  
Oral liquid medicines are commonly prepared 
extemporaneously because of a relative lack 
of licensed formulations for children who 
are unable to swallow tablets or capsules, 
or for whom the required dose is less than a 
single tablet or capsule. 7 A large proportion 
of extemporaneous compounding lies in 
converting capsules and tablets to oral 
liquids or powders. Others are made from the 
bulk active ingredient, such as oseltamivir 
powder to prepare oseltamivir phosphate 
solution. 
It can be noted that most medications 
are marketed without adequate studies 
and availability of appropriate dosages for 
infants and children.9 Even medications 
such as phenobarbital and spironolactone, 
which have been approved for use in 
paediatric patients, are not available in an 
appropriate dosage form for this category of 
patients. One of the aims of extemporaneous 
compounding is making medicines available 
to paediatric patients.10  
Legal considerations 
Extemporaneous compounding of medicines 
is usually not covered by the manufacturer in 
the product’s SmPC. An off-license form must 
be ﬁlled in by the prescriber every time there 
is a new request for an extemporaneous 
formulation, wherein the prescriber takes 
full responsibility for the clinical use of the 
preparation. This should accompany every 
new prescription. At MDH, off-license forms 
can either be departmental (e.g. caffeine 
citrate oral liquid is used by Neonatal and 
Paediatric Intensive Care Unit (NPICU) in 
neonates for respiratory distress syndrome) 
or patient-speciﬁc (e.g. sildenaﬁl suspension 
for pulmonary hypertension in paediatrics) 
and are downloadable from the hospital 
intranet via the following link: http://
www.kura.gov.mt/infocentre/forms/result.
asp?keys=off-license&SearchMonth=&Searc
hYear=. A database of off-license medicinal 
products is kept by Quality Assurance (QA) 
section within the Pharmacy Department. 
The role of QA is to ensure that services and 
medicinal products provided/supplied by 
the Pharmacy Department are of the quality 
required for their intended use.
Key points for consideration prior to 
compounding 
The following alternatives should be 
considered before extemporaneous 
compounding is undertaken:
1. Soluble or dispersible tablets may be a 
useful and convenient alternative to the 
preparation of liquid extemporaneous 
products. Some tablets can be dispersed 
or crushed and information on this aspect 
can be obtained from the Medicines 
Information Section within MDH.  In this 
case, the dose should be prepared and 
administered immediately. In general 
compressed tablets or tablets which are 
scored or just ﬁlm coated can be crushed 
whereas modiﬁed release tablets cannot.
2. If a particular medicine is not available 
as a liquid formulation, another medicine 
from the same therapeutic classiﬁcation 
may well be used, such as the use of a 
less potent steroid rather than diluting a 
potent one. 
3. Using a suitable preparation intended 
for a different route of administration, 
for example, using an injectable solution 
orally. 
4. Use of a ‘specials’ preparation 
manufactured in licensed premises 
(Specials are medicines made in larger 
volumes by a licensed manufacturer).9  
Stability 
When evaluating the stability of a 
formulation, its chemical, physical and 
microbiological stability must be considered.1 
It is highly important that the storage 
conditions stated on the label are adhered 
to. Even where a given formulation has 
been shown to achieve suitable physical, 
chemical and microbiological stability, 
the bioavailability and palatability of the 
preparation may be unproven.
 Very few extemporaneous preparations 
are supported by any data to demonstrate 
a suitable absorption proﬁle and/
or bioequivalence with a licensed 
preparation. Other issues include concerns 
about inadequate access to equipment 
and materials needed to provide a safe 
extemporaneous dispensing service and the 
highest possible quality products. 
In order to limit degradation and 
spoilage, products are given a maximum 
shelf-life of 28 days, unless the product is 
not chemically stable, whereby the shelf-life 
is then given according to the stability of 
the respective product.7 Stability studies for 
extemporaneous preparations are usually 
conducted over small periods of time. 
Lack of stability data limits many 
medicines from being made available for 
use in paediatrics. The armamentarium of 
formulations available for extemporaneous 
compounding relies heavily on the 
availability of stability data and the 
ingredients required for compounding.  
A systematic approach to compounding at 
Mater Dei Hospital
s  Non - sterile extemporaneous 
preparations must always be compounded 
upon receipt of a prescription i.e. on 
demand. 
s  If a worksheet for the formulation 
requested is not available and a 
licensed product or alternative cannot 
be found, an appropriate formulation 
must be researched. The details of the 
new formulation are presented to the 
prescriber who endorses it. 
s   A new worksheet and label must then 
be prepared. The master worksheets are 
then approved by the Quality Assurance 
section and endorsed by the Head of 
Pharmacy. A request for inclusion of the 
new extemporaneous formulation in the 
hospital formulary should also be ﬁlled 
in. The original master work sheets are 
stored by Quality Assurance section 
which is also responsible for uploading 
a secured electronic version on the 
intranet. A separate set of worksheets 
and labels are drawn up for every 
preparation compounded (i.e. patient-
speciﬁc).  
s  All pharmacists and pharmacy technicians 
receive training which is certiﬁed by 
Quality Assurance prior to starting duties 
within the Compounding Section.  All the 
compounding steps are double-checked 
by a pharmacist before a preparation is 
released for use.
Premises 
At MDH, extemporaneous medicines are 
prepared in a clean controlled environment 
containing equipment required for 
extemporaneous compounding such as a 
fume cupboard and a powder-containment 
cabinet for personnel protection from fumes 
and aerosols generated during compounding.  
Personnel must don the prescribed garments 
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before entering the clean area i.e. mob hat, 
gloves, overshoes, plastic overcoat and a 
facial mask for males. 
Final comment
The pharmaceutical industry is expected 
to develop and market dosage forms which 
are suitable for children, hence relieving 
the hospital pharmacy from the burden of 
preparing extemporaneous preparations. 
However, it remains to be discussed whether 
this is a realistic expectation. Manufacturers 
would have to produce formulations that 
have a limited shelf life, since many existing 
medicines are intrinsically unstable in any 
aqueous vehicle, which is possibly the only 
acceptable formulation for paediatric oral 
administration. The manufacturer would 
be placed at a ﬁnancial disadvantage, 
considering the small size of the paediatric 
healthcare market and the economic push for 
group purchasing and cost reduction, in 
order to solve the compounding problems 
of hospital pharmacies. 10 
Conclusion
The aim of extemporaneous compounding 
is that of meeting the therapeutic 
needs of vulnerable patients, especially 
the paediatric population, as a last 
resort in the absence of a marketed 
licensed preparation. Prescribers are 
encouraged to use their clinical judgment 
when recommending extemporaneous 
formulations to their patients, and should 
monitor for safety and efﬁcacy throughout 
treatment. With the the resulting aim of 
preparing appropriate dosage forms for 
paediatric use, a signiﬁcant responsibility 
in a pharmacists’ work remains the 
compounding of extemporaneous 
formulations. 
Acknowledgements
The author would like to thank Mr Mario 
Barbara, Senior Pharmacist, Quality 
Assurance for reviewing the document. 
References
1. Shargel L. et al. Comprehensive Pharmacy 
Review. Third Edition. USA: Lippincott Williams 
and Wilkins; 1997.
2. Jew R, Mullen R, Soo-Hoo W. Extemporaneous 
Formulations. Bethesda: American Society of 
Health-System Pharmacists, Inc.; 2003.
3. European Medicines Agency. Pediatric 
Formulations. [Internet]. Available from: http://
www.ema.europa.eu/ema/index.jsp?curl=pages/
regulation/general/general_content_000045.
jsp&mid=WC0b01ac05800260a6  (accessed 6th 
June 2013).
4. Taketomo C, Hodding J, Kraus D. Pediatric and 
Neonatal Dosage Handbook. Nineteenth Edition. 
USA: American Pharmacists Association ®, 2012.
5. European Medicines Agency. Medicines for 
Children.  [Internet]. Available from: http://
www.ema.europa.eu/ema/index.jsp?curl=pages/
special_topics/general/general_content_000302.
jsp&mid=WC0b01ac058002d4ea (accessed 6th 
June 2013).
6. Royal College of Paediatrics and Child Health. 
Medicines for Children. London: Hobbs the 
Printers Limited; 2003. 
7. Jackson M and Lowey A. Handbook of 
Extemporaneous Preparation. London: 
Pharmaceutical Press; 2010. 
8. Marriot J et al. Pharmaceutical Compounding 
and Dispensing. Second Edition. London: 
Pharmaceutical Press; 2010. 
9. Costello I. et al. Paediatric Drug Handling. 
London: Pharmaceutical Press; 2007.
10. Nahata M, Pai V and Hipple T. Pediatric Drug 
Formulations. Fifth Edition. USA: Harvey 
Whitney Book Company; 2004. 
 
Key Points 
s  Extemporaneous compounding is the preparation, mixing, assembling, packaging 
and labelling of a medicinal product based on a prescription order from a licensed 
practitioner for the individual patient.1
s  The extemporaneous compounding of medicines, involving the alternation of a 
licensed formulation, is off-license unless it is clearly indicated in the Summary of 
Product Characteristics (SmPC) of the product that the extemporaneous process can 
be performed. 
s  Extemporaneous preparations have a limited shelf life. 
s  A licensed, commercially available preparation is always preferable and in its 
absence, if possible, a licensed alternative should be sought. 
s  Extemporaneous preparations are patient-speciﬁc. 
